Comparative Effectiveness and Safety of Upadacitinib and Vedolizumab in Biologic-Experienced Patients With Ulcerative Colitis: A Retrospective Study.

ABSTRACT:

Objectives

Upadacitinib (UPA) and vedolizumab (VDZ) have been approved to treat moderate-to-severe ulcerative colitis (UC); however, direct comparative data between these two regimens are lacking. We aimed to compare the effectiveness and safety of UPA and VDZ among patients with moderate-to-severe UC who had previously been treated with advanced therapies.

Methods

Patients with moderate-to-severe UC receiving VDZ or UPA for at least 14 weeks following advanced therapy failure, including at least one anti-tumor necrosis factor (TNF) agent, between 2015 and 2024, were retrospectively recruited. Clinical response and remission were defined by the Partial Mayo Score and the Simple Clinical Colitis Activity Index. The safety profile during the treatment was also compared.

Res

SUBMITTER: Sror N 

PROVIDER: S-EPMC12681388 | biostudies-literature | 2025 Sep-Oct

REPOSITORIES: biostudies-literature